Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A

Vaccine

Volumn 16, Issue 20, 1998, Pages 1993-1999

  Thompson, H S G ^a   Davies, M L ^a   Watts, M J ^a   Mann, A E ^a   Holding, F P ^a   O'Neill, T ^a   Beech, J T ^b   Thompson, S J ^b   Leesman, G D ^c   Ulrich, J T ^c  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; Genital warts; HPV; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MPL; PHOSPHORYL LIPID A; RECOMBINANT PAPILLOMA VIRUS TYPE 6 L2E7 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONDYLOMA; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG FORMULATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; SEROLOGY; VACCINATION; VACCINE PRODUCTION; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIGENS, VIRAL; CONDYLOMATA ACUMINATA; HUMANS; INTERFERON TYPE II; LIPID A; MALE; MICE; MICE, INBRED CBA; ONCOGENE PROTEINS, VIRAL; RABBITS; RECOMBINANT FUSION PROTEINS; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 0032374338     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00088-7     Document Type: Article

References (29)

1. 1 Shah, K.V. and Howley, P.M. Papillomaviruses. In: Virology, 2nd edn (Eds Fields, B.N. and Knipe, D.M.). Raven Press, New York, 1990, Chapter 59, pp. 1651-1676.
2. 2 Beutner, K.R. and Ferenczy, A. Therapeutic approaches to genital warts. Am. J. Med. 1997, 102(5A), 28-37.
3. 3 Coleman, N., Birley, H.D.L., Renton, A.M., Hanna, N.F., Ryait, B.K., Byrne, M., Taylor-Robinson, D. and Stanley, M.A. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 1994, 102, 768-774.
4. 4 Scarpini, C.G., Coleman, N., Hanna, N.F., Weber, J., Bol, R., Hooker, J. and Stanley, M.A. Cytokine profile in regressing and non-regressing HPV infected genital warts. Submitted.
5. 5 Powell, L.C., Pollard, M. and Jinkins, J.L. Treatment of condyloma acuminata by autogenous vaccine. South. Med. J. 1970, 63, 202-205.
6. 6 Jarrett, W.F.H., Smith, K.T., O'Neil, B.W., Gaukroger, J.M., Chandrachud, L.M., Grindlay, G.J. and Campo, M.S. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 1991, 184, 33-42.
7. 7 Campo, M.S., Grindlay, G.J., O'Neill, B.W., Chandrachud, L.M., McGarvie, G.M. and Jarrett, W.F. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J. Gen. Virol. 1993, 74, 945-953.
8. 8 Kirnbauer, L.M., Chandrachud, L.M., O'Neill, B.W., Wagner, E.R., Grindlay, G.J., Armstrong, A., McGarvie, G.M., Schiller, J.T., Lowy, D.R. and Campo, M.S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996, 219, 37-44.
9. 9 Selvakumar, R., Borenstein, L.A., Lin, Y.-L., Ahmed, R. and Wettstein, F.O. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J. Virol. 1995, 69, 602-605.
10. 10 Thompson, H.S.G., Davies, M.L., Holding, F.P., Mann, A.E., Fallon, R.E., O'Neill, T. and Roberts, J.S. Phase I safety and immunogenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Submitted.
11. 11 Lacey, C.J.N., Thompson, H.S.G., Davies, M.L., O'Neill, T., Holding, F.P., Fallon, R.E., Monteiro, E.F. and Roberts, J.S. Phase IIa study of a recombinant fusion protein vaccine for the treatment of genital warts. Submitted.
12. 12 Ulrich, J.T. and Myers, K.R. Monophosphoryl lipid A as an adjuvant. In: Vaccine Design: The Subunit and Adjuvant Approach (Eds Powell, M.P. and Newman, M.J.). Plenum Press, New York, 1995, pp. 495-524.
13. 13 Rudbach, J.A., Johnson, D.A. and Ulrich, J.T. Ribi adjuvants: chemistry, biology and utility in vaccines for human and veterinary medicine. In: The Theory and Practical Application of Adjuvants (Ed. Stewart-Tull, D.E.S.). John Wiley, Chichester, 1995, pp. 287-313.
14. 14 Lemaire, G., Tenu, J., Petit, J. and Lederer, E. Natural and synthetic trehalose diesters as immunomodulators. Med. Res. Rev. 1986, 6, 243-274.
15. 15 Baldridge, J.R. and Ward, J.R. Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity. Vaccine 1997, 15, 395-401.
16. 16 Beech, J.T., Bainbridge, T. and Thompson, S.J. Incorporation of cells into an ELISA system enhances antigen-driven lymphokine detection. J. Immunol. Meth. 1997, 205, 163-168.
17. 17 Bailey, M., Williams, N.A., Wilson, A.D. and Stokes, C.R. PROBIT: weighted probit regression analysis for estimation of biological activity. J. Immunol. Meth. 1992, 153, 261-262.
18. 18 VanCott, T.C., Mascola, J.R., Kaminski, R.W., Kalyanaraman, V., Hallberg, P.L., Burnett, P.R., Ulrich, J.T., Rechtman, D.J. and Birx, D.L. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 1997, 71, 4319-4330.
19. 19 Lindblad, E.B. Aluminium adjuvants. In: The Theory and Practical Application of Adjuvants (Ed. Stewart-Tull, D.E.S.). John Wiley, Chichester, 1995, p. 21.
20. 20 Lofthouse, S.A., Andrews, A.E., Nash, A.D. and Bowles, V.M. Humoral and cellular responses induced by intradermally administered cytokine and conventional adjuvants. Vaccine 1994, 13, 1131-1137.
21. 21 Dillon, S.B., Demuth, S.G., Schnieder, M.A., Weston, C.B., Jones, C.S., Young, J.F., Scott, M., Bhatanger, P.K., LoCastro, S. and Hanna, N. Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant. Vaccine 1992, 10, 309-318.
22. 22 O'Hagan, D.T., Ott, G.S. and Van Nest, G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today 1997, 3(2), 69-75.
23. 23 Gordon, D.M., McGovern, T.W., Krzych, U., Cohen, J.C., Schneider, I., LaChance, R., Heppner, D.G., Yuan, G., Hollingdale, M., Slaoui, M., Hauser, P., Voet, P., Sadoff, J.C. and Ballou, W.R. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 1995, 171, 1576-1585.
24. 24 Neuzil, K.M., Johnson, J.E., Tang, Y.-W., Prieels, J.-P., Slaoui, M., Garcon, N. and Graham, B.S. Adjuvants influence the quantitative and qualitative immune response in Balb/c mice immunised with respiratory syncitial virus FG subunit vaccine. Vaccine 1997, 15, 525-532.
25. 25 Keadle, T.L., Laycock, K.A., Miller, J.K., Hook, K.K., Fenoglio, E.D., Francotte, M., Slaoui, M., Stuart, P.M. and Pepose, J.S. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. J. Infect. Dis. 1997, 176, 331-338.
26. 26 Leroux-Roels, G., Moreux, E., Verhasselt, B., Birneaux, S., Brulein, V., Francotte, M., Slaoui, M. and Vandepapeliere, P. Immunogenicity and reactogenicity of a recombinant HSV-2 glycoprotein D vaccine with or without monophosphoryl lipid A in HSV seronegative and seropositive subjects. 33rd Intersci. Conf. Antimicrob. Agents Chemother. 1993, 2209, 341.
27. 27 Thoelen, S., Van Damme, P., Meeus, A., Collard, F., Slaoui, M. and Vandepapeliere, P. Immunogenicity of a recombinant hepatitis B vaccine with monophosphoryl lipid A administered following various two dose schedules. 33rd Intersci. Conf. Antimicrob. Agents Chemother. 1993, 340, 182.
28. 28 Van Damme, P., Thoelen, S., Van Passchen, M., Leroux-Roels, G., Meeus, A., Slaoui, M. and Vandepapeliere, P. Safety, humoral and cellular immunity of a recombinant hepatitis B vaccine with monophosphoryl lipid A in healthy volunteers. 33rd Intersci. Conf. Antimicrob. Agents Chemother. 1993, 667, 241.
29. 29 Stoute, J.A., Slaoui, M., Heppner, D.G., Momin, P., Kester, K.E., Desmons, P., Wellde, B.T., Garcon, N., Krzych, U., Marchand, M., Ballou, W.R. and Cohen, J.D. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 1997, 336, 86-91.